Person: SEÇKİN GENÇOSMANOĞLU, DİLEK
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SEÇKİN GENÇOSMANOĞLU
First Name
DİLEK
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Secukinumab and infectious adverse effects: A real-life experience of 63 psoriasis patients(2021) SEÇKİN GENÇOSMANOĞLU, DİLEK; Ergun, Tulin; Seckin, Dilek; Demir, Gizem; Direskeneli, HanerPublication Open Access Drug eruption: A mimicker of Coronavirus disease-2019 rash(2022-01-01) ERGUN, SAFİYE ATLAS TÜLİN; SEVEN, SEDA; SEÇKİN GENÇOSMANOĞLU, DİLEK; TİGEN, ELİF; AKTAŞ, MERYEM; ERGUN S. A. T., Ergenc I., SEVEN S., SEÇKİN GENÇOSMANOĞLU D., CÖMERT ÖZER E., AKTAŞ M., TİGEN E.Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.Publication Metadata only Erosive pustular dermatosis of the leg in a young girl successfully treated with sulfasalazine and 308 nm monochromatic excimer light(2020) SEÇKİN GENÇOSMANOĞLU, DİLEK; Seckin, Dilek; Tekin, Burak; Güneş, Pembegül; Demirçay, ZeynepPublication Metadata only The impact of antipsoriatic treatment on serum pro-BDNF, BDNF levels, depression, anxiety scores, and quality of life(WILEY, 2021) SEÇKİN GENÇOSMANOĞLU, DİLEK; Aksoy, Hasan; Ergun, Tulin; Akkiprik, Mustafa; Eyuboglu, Irem Peker; Gencosmanoglu, Dilek Seckin; Unalan, Gulru Pemra Cobek; Yoney, HakanDepression is a comorbidity of psoriasis. Suppression of neurotrophins has been proposed to cause depression. Peripheral brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF have been shown to be altered in depression. To compare serum pro-BDNF and BDNF levels, depression, anxiety, and quality of life (QoL) in psoriasis patients, diseased, and healthy controls, to assess impact of 12-week antipsoriatic treatment on abovementioned markers. At baseline, all groups completed Beck Depression Inventory (BDI), Spielberger State-Trait Anxiety Inventory-II (STAI-II) and DLQI; serum BDNF, proBDNF levels were measured. These were repeated after 3-months of treatment in psoriasis patients. Depression and anxiety were significantly higher, QoL was poorer in psoriasis. ProBDNF and proBDNF/BDNF ratios were not different among groups at baseline but significantly decreased after treatment in psoriasis. Depression and QoL improved significantly, BDNF and anxiety scores did not change. Altered pro-BDNF and proBDNF/BDNF ratios may have a role in depression pathogenesis in psoriasis. Antipsoriatic treatment causes improvement in depression, QoL, and reduction of proBDNF and proBDNF/BDNF ratios. Effective disease control may reverse dysregulated neurotrophin pathways and its consequences like depression.Publication Open Access Psychiatric Disorders, Family Functions, and Parent Psychiatric Symptoms in Children and Adolescents with Chronic Dermatological Diseases Treated with Phototherapy(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2021) SEÇKİN GENÇOSMANOĞLU, DİLEK; Ayyildiz, Didem; Fis, Nese Perdahli; Gumustas, Funda; Seckin, DilekObjective: The aim of this study was to examine comorbid psychiatric disorders, family functioning, and parental psychiatric symptoms in children and adolescents with chronic dermatological diseases and compare them with those of healthy controls. Materials and Methods: The research sample consisted of patients between the age of 9 and 18 years (n = 45) with alopecia areata, vitiligo, or psoriasis and a control group (CG) of healthy children and adolescents of the same age (n = 42). The psychiatric diagnoses of cases were established using Schedule for Affective Disorders and Schizophrenia for School Aged Children Present-Lifetime Version. Family assessment device (FAD) was used to evaluate family functioning levels. Parental psychiatric symptom levels were obtained by the Symptom Checklist-90-R. Results: Children and adolescents with chronic dermatological diseases had significantly higher rates of any anxiety disorders and any axis I comorbid psychiatric disorders than healthy controls after adjusting for socioeconomic status (P < 0.05). There were no significant differences in parental psychiatric symptom levels and family functioning levels between two groups; however, families of patients with comorbid psychiatric disorders had significantly higher scores in problem-solving and communication subscales of the FAD when compared to those of patients without psychiatric disorders and CG. Conclusions: Our findings suggest that children and adolescents with chronic dermatological diseases have higher risk for anxiety disorders. When psychiatric disorders co-occur with the dermatological disease in children and adolescents, they may adversely affect the family functioning, in the domains of problem-solving and communication skills.